中文名 |
1,3-二丙基-8-p-硫化苯基黄嘌呤 |
---|---|
英文名 |
4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)benzenesulfonic acid |
中文别名 |
1,3-二丙酯-8-P-三苯基黄嘌呤 | 1,3-二丙基-8-对质硫苯基黄嘌呤 |
英文别名 |
更多 |
密度 | 1.405g/cm3 |
---|---|
熔点 | >300?C |
分子式 | C17H20N4O5S |
分子量 | 392.43000 |
精确质量 | 392.11500 |
PSA | 135.43000 |
LogP | 2.70080 |
折射率 | 1.607 |
储存条件 |
密闭,阴凉,干燥处 |
稳定性 |
按规定使用和贮存的不会分解,避氧化物 |
分子结构 |
1、 摩尔折射率:96.51 2、 摩尔体积(m3/mol):279.1 3、 等张比容(90.2K):779.7 4、 表面张力(dyne/cm):60.8 5、 极化率(10-24cm3):38.26 |
计算化学 |
1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:6 4.可旋转化学键数量:6 5.互变异构体数量:4 6.拓扑分子极性表面积132 7.重原子数量:27 8.表面电荷:0 9.复杂度:671 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 |
1. 性状:白色固体 2. 密度(g/mL25?C):未确定 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(?C):>300 5. 沸点(?C,常压):未确定 6. 沸点(?C20mmHg):未确定 7. 折射率:未确定 8. 闪点(?F):未确定 9. 比旋光度(?):未确定 10. 自燃点或引燃温度(?C):未确定 11. 蒸气压(Pa,):未确定 12. 饱和蒸气压(kPa,60?C):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(?C):未确定 15. 临界压力(KPa):未确定 16. 油水(正辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:H2O: 0.43 mg/mL |
个人防护装备 |
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
---|---|
安全声明 (欧洲) |
S22-S24/25 |
危险品运输编码 | NONH for all modes of transport |
海关编码 | 2933990090 |
~%
1,3-二丙基-8-p-硫化苯基黄嘌呤
89073-57-4
|
文献:Journal of Medicinal Chemistry, , vol. 28, # 4 p. 487 – 492 |
~%
1,3-二丙基-8-p-硫化苯基黄嘌呤
89073-57-4
|
文献:Journal of Medicinal Chemistry, , vol. 28, # 4 p. 487 – 492 |
~%
1,3-二丙基-8-p-硫化苯基黄嘌呤
89073-57-4
|
文献:Journal of Medicinal Chemistry, , vol. 28, # 4 p. 487 – 492 |
~%
1,3-二丙基-8-p-硫化苯基黄嘌呤
89073-57-4
|
文献:Journal of Medicinal Chemistry, , vol. 28, # 4 p. 487 – 492 |
1,3-二丙基-8-p-硫化苯基黄嘌呤上游产品? 3 | |
---|---|
|
|
1,3-二丙基-8-p-硫化苯基黄嘌呤下游产品? 1 | |
|
海关编码 | 2933990090 |
---|---|
中文概述 | 2933990090. 其他仅含氮杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Extracellular 2′,3′-cAMP-adenosine pathway in proximal tubular, thick ascending limb, and collecting duct epithelial cells. Am. J. Physiol. Renal Physiol. 304(1) , F49-55, (2013)
In a previous study, we demonstrated that human proximal tubular epithelial cells obtained from a commercial source metabolized extracellular 2′,3′-cAMP to 2′-AMP and 3′-AMP and extracellular 2′-AMP a…
|
|
Expression of the 2′,3′-cAMP-adenosine pathway in astrocytes and microglia. J. Neurochem. 118 , 979-987, (2011)
Many organs express the extracellular 3′,5′-cAMP-adenosine pathway (conversion of extracellular 3′,5′-cAMP to 5′-AMP and 5′-AMP to adenosine). Some organs release 2′,3′-cAMP (isomer of 3′,5′-cAMP) and…
|
|
Sustained reduction in myocardial reperfusion injury with an adenosine receptor antagonist: possible role of the neutrophil chemoattractant response. J. Pharmacol. Exp. Ther. 292(3) , 929-38, (2000)
Recent studies have demonstrated that three membrane-permeant A(1) receptor antagonists reduced infarct size in a model of ischemia followed by brief reperfusion. However, it was not determined whethe…
|
|
1,3-Dspx |
4-(2,3,6,7-Tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-benzenesulfonic acid |
Benzenesulfonic acid,4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl) |
DPSPX |
PSPX |
1,3-Dipropyl-8-(p-sulfophenyl)xanthine |
4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)benzenesulfonic acid |
MFCD00055080 |